



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Group Art Unit: 1621
Michael L. VAZQUEZ *et al.*) Examiner: Nagubandi, L.
Serial No. 10/750,213) Atty. Docket 101765.00005 (2703/9/Div)
Filed: January 2, 2004)

CONFIRMATION NO. 6652

For: SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

REQUEST FOR CONSIDERATION OF PREVIOUSLY FILED REFERENCES

U.S. Patent and Trademark Office
401 Dulany Street
Alexandria, VA 22314

Sir:

Applicants respectfully request consideration of information previously submitted in an Information Disclosure Statement (IDS) filed on January 2, 2004.

No fee is believed to be due for this submission. However, should a fee be required, the Commissioner is hereby authorized to debit our Deposit Account No. 19-0733, as necessary.

A review of the returned and initialed forms PTO-1449 and PTO/SB/08 indicates that several of the references cited in the IDS filed January 2, 2004 were crossed out and/or not initialed. It is presumed therefore that these non-considered references are missing from the file of parent Application Serial No. 09/655,844 and/or other prior applications, relied upon for priority under 35 U.S.C. § 120, in which copies of the references were initially provided. In accordance with 37 C.F.R. 1.98(d), Applicants were not required to submit copies of these references.


Nevertheless, copies of these previously filed references, which are listed in the attached Forms PTO/SB08/a and b, have now been obtained and are being submitted herewith.

Consideration of these references is again respectfully requested, together with a return of the enclosed forms PTO/SB/08a and 08b initialed by the Examiner indicating the same.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: February 6, 2007

By: 
Joseph M. Skerpon
Registration No. 29,864

Customer No. 22907




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

<i>Application Number</i>	10/750,213
<i>Filing Date</i>	January 2, 2004
<i>First Named Inventor</i>	Michael L. Vazquez
<i>Art Unit</i>	1621
<i>Examiner Name</i>	Nagubandi, L.
<i>Attorney Docket Number</i>	101765.00005 (2703/9/Div)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		EPO 0 346 847	12-20-1989			
		EPO 0 172 347	02-26-1986			
		AU 79823/87	04-28-1988			

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

2

Complete if Known	
Application Number	10/750,213
Filing Date	January 2, 2004
First Named Inventor	Michael L. Vazquez
Art Unit	1621
Examiner Name	Nagubandi, L.
Attorney Docket Number	101765.00005 (2703/9/Div)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sax, N.I., "Dangerous Properties of Industrial Materials", 6 th Ed., Van Nostrand Reinhold Co., 1984, p. 443	
		"Handbook of Reactive Chemical Hazards", 3 rd Ed., Butterworths, 1985, p. 295	
		Reetz et al., Phil. Trans. R. Soc. Lond., 326: 573-578 (1988)	
		Erickson et al., <u>Science</u> , 249; 527-533 (1980)	
		Drugs of the Future, 1991, 16(3), 210-212	
		Pept. Struct. Funct. Proc. AM. Prept. Sym. 8 th ed. by V.J. Hunby and D.H. Rich, "Design of Protease Inhibitors," Rich, Saluturo & Holladay pp. 511-520 (1983)	
		McQuade et al., "A Synthesis HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation", <u>Science</u> , 247, 454 (1990)	
		Fittkau, <u>J. Prakt. Chem.</u> 315, 1037-1044 (1973)	
		Michnick et al., <u>Synlett</u> , 9:631-2 (1991)	
		Hoffman et al., <u>J. Chem. Soc., Chem. Comun.</u> (1991);195-196	
		Gu et al., <u>Chemistry Letters</u> (1992):1169-1172	
		Harada et al., <u>Chem Pharm. Bull.</u> , 37, (9):2570-2572 (1989)	
		Pawless et al., "Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds," <u>J. Virol. Methods</u> , 20: 309-321 (1988)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.